CALGARY, Sept. 9, 2015 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics
Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the
Baird 2015 Healthcare Conference in a session on Thursday, September 10th, 2015 at
10:50 a.m. ET. The
conference takes place on September
9th and 10th in New York, NY at the New York Palace Hotel.
A live audio link to the webcast session will be available at
http://wsw.com/webcast/baird43/oncy or on the company's website at
http://www.oncolyticsbiotech.com/for-investors/presentations.
It is recommended that listeners log on 10 minutes in
advance of a live session to register and download any necessary
software. An audio replay will be accessible approximately two
hours following the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a
Calgary-based biotechnology
company focused on the development of oncolytic viruses as
potential cancer therapeutics. Oncolytics' clinical program
includes a variety of later-stage, randomized human trials in
various indications using REOLYSIN®, its proprietary
formulation of the human reovirus. For further information about
Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This
release and the presentation related thereto contain
forward-looking statements which involve known and unknown risks,
delays, uncertainties and other factors not under the Company's
control and which may cause actual results, performance or
achievements of the Company to be materially different from the
results, performance or expectations implied by these
forward-looking statements. Such risks and uncertainties
include, among others, the efficacy of REOLYSIN as a cancer
treatment, the success and timely completion of clinical studies
and trials, uncertainties related to the research and development
of pharmaceuticals and uncertainties related to the regulatory
process. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company
does not undertake to update these forward-looking statements,
except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
